Often times, I'm reminded of the beauty of corporate partnerships. Yesterday was one of those times. I read the title, "Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology," and thought to myself, "What a perfect partnership." Here's two companies leveraging their core capabilities in a perfectly complimentary way.
The collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.
The article went on to say, "Ultimately, the technology has the potential to improve throughput and reduce costs to achieve the vision of whole human genome sequencing at a cost of $100 to $1,000. Having access to an individual's personal genome could allow personalization of medical care."
Obviously, this has enormous implications for the future of health care - implications that would take five more blog posts to cover. But one thing is for sure: if the partnership proves successful, this could be a major disruptor in drug development.
No comments:
Post a Comment